Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $275.00 | 2 | 59.3% |
| Unspecified | $125.00 | 1 | 26.9% |
| Food and Beverage | $63.29 | 3 | 13.6% |
| Education | $0.65 | 1 | 0.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Indivior Inc. | $268.14 | 4 | $0 (2024) |
| Alkermes, Inc. | $167.02 | 2 | $0 (2019) |
| AbbVie Inc. | $28.78 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17.49 | 1 | Indivior Inc. ($17.49) |
| 2023 | $28.78 | 1 | AbbVie Inc. ($28.78) |
| 2019 | $267.67 | 4 | Indivior Inc. ($250.65) |
| 2017 | $150.00 | 1 | Alkermes, Inc. ($150.00) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: OUD | ||||||
| 05/25/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $28.78 | General |
| Category: IMMUNOLOGY | ||||||
| 10/22/2019 | Indivior Inc. | SUBLOCADE (Drug) | Education | In-kind items and services | $0.65 | General |
| Category: OUD | ||||||
| 09/12/2019 | Indivior Inc. | SUBLOCADE (Drug) | Consulting Fee | Cash or cash equivalent | $125.00 | General |
| Category: OUD | ||||||
| 07/18/2019 | Indivior Inc. | SUBOXONE (Drug) | — | Cash or cash equivalent | $125.00 | Research |
| Study: Quantitative Testing of Prescriber Knowledge, Attitudes and Behavior about SUBOXONE buprenorphine and naloxone Sublingual Film CIII Safety and Use Information • Category: OUD | ||||||
| 03/09/2019 | Alkermes, Inc. | VIVITROL (Drug) | Food and Beverage | In-kind items and services | $17.02 | General |
| Category: CNS | ||||||
| 06/27/2017 | Alkermes, Inc. | — | Consulting Fee | Cash or cash equivalent | $150.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Quantitative Testing of Prescriber Knowledge, Attitudes and Behavior about SUBOXONE buprenorphine and naloxone Sublingual Film CIII Safety and Use Information | Indivior Inc. | $125.00 | 1 |
About Dr. Michael Coburn, MD
Dr. Michael Coburn, MD is a Addiction Medicine healthcare provider based in North Kingstown, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1720040728.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Coburn, MD has received a total of $463.94 in payments from pharmaceutical and medical device companies, with $17.49 received in 2024. These payments were reported across 7 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($275.00).
Practice Information
- Specialty Addiction Medicine
- Other Specialties Substance Use Disorder
- Location North Kingstown, RI
- Active Since 04/05/2006
- Last Updated 10/04/2025
- Taxonomy Code 2084A0401X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1720040728
Products in Payments
- SUBLOCADE (Drug) $143.14
- SUBOXONE (Drug) $125.00
- RINVOQ (Biological) $28.78
- VIVITROL (Drug) $17.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.